Analysts expect that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will report earnings of ($1.02) per share for the current quarter, Zacks reports. Four analysts have made estimates for Aerie Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.96) and the lowest estimate coming in at ($1.09). Aerie Pharmaceuticals reported earnings per share of ($1.38) in the same quarter last year, which would indicate a positive year over year growth rate of 26.1%. The company is expected to report its next earnings report on Wednesday, February 27th.
According to Zacks, analysts expect that Aerie Pharmaceuticals will report full year earnings of ($4.72) per share for the current fiscal year, with EPS estimates ranging from ($4.84) to ($4.60). For the next fiscal year, analysts forecast that the company will report earnings of ($2.24) per share, with EPS estimates ranging from ($3.35) to ($1.45). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings results on Tuesday, November 6th. The company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.33) by ($0.40). The business had revenue of $7.30 million during the quarter, compared to the consensus estimate of $5.63 million.
Shares of NASDAQ:AERI traded down $1.18 on Friday, hitting $39.89. 727,832 shares of the company’s stock were exchanged, compared to its average volume of 699,558. The stock has a market cap of $1.87 billion, a P/E ratio of -11.84 and a beta of 0.99. Aerie Pharmaceuticals has a 1-year low of $38.50 and a 1-year high of $74.75.
In other Aerie Pharmaceuticals news, CFO Richard J. Rubino sold 66,605 shares of the stock in a transaction that occurred on Thursday, September 27th. The stock was sold at an average price of $60.23, for a total transaction of $4,011,619.15. Following the completion of the sale, the chief financial officer now directly owns 334,236 shares of the company’s stock, valued at approximately $20,131,034.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Casey C. Kopczynski sold 11,000 shares of the stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $60.09, for a total value of $660,990.00. Following the sale, the insider now directly owns 148,517 shares of the company’s stock, valued at $8,924,386.53. The disclosure for this sale can be found here. Insiders have sold a total of 134,117 shares of company stock valued at $8,007,926 over the last ninety days. 10.53% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the business. Columbus Circle Investors raised its stake in shares of Aerie Pharmaceuticals by 3.1% during the 3rd quarter. Columbus Circle Investors now owns 798,376 shares of the company’s stock worth $49,140,000 after buying an additional 24,196 shares in the last quarter. Amalgamated Bank raised its stake in shares of Aerie Pharmaceuticals by 20.0% during the 2nd quarter. Amalgamated Bank now owns 5,441 shares of the company’s stock worth $368,000 after buying an additional 906 shares in the last quarter. BlackRock Inc. raised its stake in shares of Aerie Pharmaceuticals by 9.0% during the 2nd quarter. BlackRock Inc. now owns 2,991,101 shares of the company’s stock worth $202,049,000 after buying an additional 246,686 shares in the last quarter. UBS Group AG raised its stake in shares of Aerie Pharmaceuticals by 142.3% during the 1st quarter. UBS Group AG now owns 9,409 shares of the company’s stock worth $511,000 after buying an additional 5,526 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Aerie Pharmaceuticals by 5.7% during the 2nd quarter. Northern Trust Corp now owns 458,235 shares of the company’s stock worth $30,954,000 after buying an additional 24,687 shares in the last quarter.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Further Reading: What is an SEC Filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.